Second STOP After Pioglitazone Priming in CML Patients

Single-center study, prospective, phase II trial. The study objectives are : * To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI discontinuation. * To assess survival without loss of MMR over a 12 months period following a second TKI discontinuation in subjects who achieve or maintain \< MR4.5 with the combination PIO and TKI administered for at least 6 months.

Trial Details

NCT ID
NCT02889003
Phase
PHASE2
Sponsor
Versailles Hospital
Status
RECRUITING
Cancer Type
Chronic Myeloid (CML) Leukemia
Interventions
  • Pioglitazone + TKI
Locations (sample)
  • Le Chesnay, France|48.8222,2.12213
  • Le Kremlin-Bicêtre, France|48.81471,2.36073
  • Lyon, France|45.74906,4.84789
  • Nantes, France|47.21725,-1.55336
  • Rennes, France|48.11109,-1.67431

Key Eligibility Criteria

  • CML in any phase. patient in MR4
  • Loss of MMR following a first or subsequent TKI discontinuation trial.
  • Patient prior treated with imatinib, dasatinib, nilotinib, or bosutinib
  • Age \>18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Myeloid (CML) Leukemia Trials on Trialify →